Previous studies on rat beta cells in vitro have suggested that insulin release is synergistically regulated by signalling molecules derived from glucose metabolism on the one hand and adenylate cyclase stimulation by glucagon or related peptides on the other [1±3]. In rodent beta cells, regulation of the cAMPdependent signalling pathway has been shown [3±7] to depend on expression of specific receptors for glucagon-like peptide-1-(7±36) amide (GLP-1), glucosedependent insulinotropic polypeptide (GIP) and glucagon. The gastrointestinal hormones GLP-1 and GIP effectively increase glucose-induced insulin release in vitro [8±10]; their pivotal role as incretin hormones has been recently illustrated in two mouse models with homozygous null mutations in the respective genes [11, 12] . It is not clear whether similar mechanisms operate in human beta cells. More than three decades ago insulin release in humans was shown to be dually stimulated by glucose and glucagon [13, 14] , the glucagon effect appearing independent of enhanced glucose mobilisation from the liver ]-glucagon-amide (n = 8; p < 0.05), indicating participation of endogenously released glucagon in the process of glucose-induced insulin release. The glucagon-receptor antagonist also suppressed the potentiation of glucose-induced insulin release by addition of 10 nmol/l glucagon. Conclusion/interpretation. These data suggest that human beta cells express functional glucagon receptors which can, similar to incretin hormone receptors, generate synergistic signals for glucose-induced insulin secretion.
. Insulin release from isolated human islets was also found to be stimulated by glucose and by phosphodiesterase inhibitors [16, 17] . Therefore, similar as was proposed for the rat [1±3] , synergism between glucose metabolism and intracellular cAMP concentrations in the regulation of insulin release from human beta cells could be present. Such signalling could be clinically relevant because defects in one of the components of beta-cell signalling in response to glucose or to cAMP could be involved in the pathophysiology of human diabetes [18] . While studying insulin release from isolated human islet preparations, we noticed similarities to and differences from glucose regulation in rodent beta cells [17, 19, 20] . We have extended this investigation to the cAMP-generating component of beta-cell regulation. Studies in vivo have shown that glucagon [14±16] as well as the gluco-incretins GLP-1 and GIP [21±24] stimulate insulin secretion in human subjects. As the human genes encoding GLP-1 receptor (R), GIP-R and glucagon receptor have been cloned [25±27], we studied receptor gene expression in isolated human islet cells, assessing the presence of mRNA and the functional importance of these receptors for glucose competence in human beta cells. For the glucagon receptor, receptor function was evaluated using des-His ]-glucagon-amide, a specific receptor antagonist [28] . Our data show that glucagon receptors contribute substantially (more than 50 %) to the glucose-induced secretory responsiveness of human islet cells.
Materials and methods
Preparation and culture of human islet cells. Human pancreatic tissue, isolated islets and duct cells were obtained as samples for analysis from a multicentre programme on betacell transplantation in diabetes [17] , which was approved by central and local ethical committees. Total RNA for RT-PCR analysis was extracted from tissue samples taken during autopsies within 8 h of death. Islet cell preparations were isolated from 12 different pancreata, (donor age 9±56 years) the most frequent causes of death of the donors (all nondiabetic) being intracranial haemorrhage (6/12) and severe head trauma (2/12). Donor organs were procured at European hospitals affiliated with Eurotransplant (Leiden, The Netherlands) and Beta-Cell Transplant (Brussels, Belgium). Cold preservation time of the organs was 13.5 1.9 h (means SEM). Islets were prepared as described previously [17] , the mean duration of isolation being 5 h, and then cultured for 2 to 5 days in Ham's F10 medium, containing 6.1 mmol/l glucose [17] . After dissociation of cultured islet preparations, more than 90 % of the cells stained positive for the vital stain neutral red; they comprised 53 8 % insulin-positive cells 15 3 % glucagon-positive cells and 38 15 % non-granulated duct cells. Dispersed human islet cells were distributed over Multiwells (Falcon, Becton Dickinson, N. J., USA) and cultured for 1 day in serum-free Ham's F10 medium containing 1 % BSA (fraction V, RIA grade, Sigma, St. Louis, Mo., USA), 0.075 mg/ml penicillin and 0.1 mg/ml streptomycin, 6.1 mmol/l glucose and 2 mmol/l glutamine. Under this condition, islet cells formed small clumps (three to ten cells) and attached loosely to the bottom. Nongranulated duct cells were prepared and cultured as described [29] . The final preparation was 90 % or more pure with less than 5 % contaminating endocrine or acinar cells.
Measurement of insulin release. Cultured islet cells were washed with glucose free Ham's F10 medium containing 1 % BSA and 2 mmol/l glutamine and distributed over Multiwells as batches of 2.5 10 4 cells. They were then statically incubated for 2 h at 37 C in 95 % air:5 % CO 2 with 1 ml Ham's F10 medium containing 1 % BSA and 2 mmol/l glutamine supplemented with 2.5 or 10 mmol/l glucose, with or without addition of glucagon, GLP-1 or GIP (10 nmol/l) or the presence of the glucagon-receptor antagonist des-His 1 -[Glu 9 ]-glucagonamide (1 mmol/l; [28] ). Glucagon, GLP-1, GIP and des-His 1 -[Glu 9 ]-glucagon-amide were purchased from Sigma. The GLP-1R antagonist exendin-(9±39)-amide [30] was kindly provided by Dr. J. Vandekerckhove (Department of Physiological Chemistry, University of Ghent, Belgium). At the end of incubation, supernatant was taken for insulin immunoassay and cell pellets were extracted for assessment of insulin content [17] . Insulin was expressed as per cent of insulin content. No difference in insulin content was observed after incubation of islet cells in 2.5 or 10 mmol/l glucose (0.25 0.04 mg/well and 0.27 0.04 mg/well, respectively n = 6). mRNA analysis. Total RNA was isolated from human control tissues and human islet cells using Gibco BRL TRIzol (Life Technologies, Merelbeke, Belgium). Qualitative RT-PCR analysis of the expression of GLP-1R, GIP-R and glucaconreceptor mRNA in human islet cells was done by reverse transcription of 0.5 mg total RNA in 10 mmol/l TRIS HCl pH 8.3, 50 mmol/l KCl, 5 mmol/l MgCl 2 with 1 mmol/l deoxyribonucleoside triphosphate (dNTP), 5 mmol/l random primers, 20 units RNase inhibitor and 50 units avian myeloblastosis virus reverse transcriptase (Perkin Elmer Cetus, Emeryville, Calif., USA). The PCR step was conducted on 5 ml of the prepared cDNA in 9 mmol/l TRIS HCl pH 8.3, 45 mmol/l KCl, 2 mmol/l MgCl 2 , 100 mmol/l dNTP, 20 pmoles of the 3'-and 5'-primers and 2.5 units of Taq polymerase (Perkin Elmer). Specific primers were designed to anneal with codons 199±206/422±429 for the published sequence of the human liver glucagon receptor [27] , codons 203±209/424±431 for the human GLP-1R [25] and codons 195±202/377±384 for the human GIP-R [26] , yielding products with expected length (689, 684 and 568 bp respectively). We used B-actin primers, designed to anneal with codons 249±255/388±244 of human b-actin (gene accession number NM001 101) as an internal control to evaluate RNA quality. The cycling profile for amplification of GIP-R, GLP-1R and glucagon-receptor cDNAs started with a single denaturation step (2.5 min, 94 C) followed by 35 cycles of (0.5 min, 94 C; 0.5 min, 60 C and 0.5 min, 72 C) each. The cycling profile for b-actin was the same except for the annealing temperature, which was 57 C. We controlled PCR products for their length on a 1.5 % agarose gel and sequenced on an ABI Prism 310 automatic sequencer (Perkin Elmer).
Northern blots were done with 20 mg total RNA per sample (fresh human islet cells, human pancreatic duct cells, total pancreas and control tissues from human cadavers) and 1.5 % agarose gels. The RNA was transferred to nylon membranes (GeneScreen, NEN Dupont, Boston, Mass., USA) according to a modified GeneScreen protocol, i. e. we used a phosphate buffer for RNA transfer instead of 2 SSC. Blots were UVcross-linked (UV StratalinkerTM1800, Stratagene, La Jolla, Calif., USA) and hybridised with 32 P-labelled cDNA glucagon receptor, GLP-1R, GIP-R and secretin-receptor probes that had been prepared by RT-PCR and that were validated for their nucleotide sequence by automated sequencing. The PCR fragments obtained were purified on QIAquick PCR purification columns (Westburg, Leusden, The Netherlands) and served as a template in a random labelling method (Amersham Life Science, Amersham, UK). After hybridisation, blots were stringently washed by incubating for 30 min at 60 C in 0.5 SSC and 2.5 % SDS; membranes were stripped and reused for hybridisation with an 18 S rRNA probe (5'-CTT CCT CTA GAT AGT CAA GTT CGA CCG TCT-3'; Medline accession number K034 325) to assess quantity and quality of blotted RNA. Autoradiographic exposure times used for this study were 1 day (glucagon-receptor and GLP-1R transcripts), 2 days (GIP-R mRNA), 5 days (secretin-receptor mRNA) and 1 h (18S probe). All experiments were repeated at least twice, giving similar results.
Statistical analysis. Insulin release data are expressed as mean values SEM of at least three independent experiments. Significance of differences between controls and experimental conditions was assessed via ANOVA, using p less than 0.05 as the accepted level of significance.
Results
Measurements of insulin release. Glucagon-like peptide-1, GIP and glucagon were tested for their effects on insulin release in the presence of 10 mmol/l glucose (Table 1) . During a 2-h static incubation at this glucose concentration, human islets released 3.5-fold more insulin than at 2.5 mmol/l glucose (p < 0.05). Glucose stimulation was amplified two-fold by 10 nmol/l of GLP-1 or GIP (Table 1) and 65 % to 85 % by 10 nmol/l glucagon ( Table 1, Fig. 1 ). To investigate whether the glucagon effect on insulin secretion is mediated by glucagon receptor or GLP-1R or both [28] , we tested the potentiating effect of 10 nmol/l glucagon in the presence or absence of the glucagonreceptor antagonist, des-His ]-glucagon-amide did not affect insulin release at 2.5 mmol/l but the peptide suppressed it at 10 mmol/l glucose by 50 % (p < 0.05) so that the presence of high glucose was no longer stimulatory in this condition (Fig. 1) . On the contrary, 1 mmol/l exendin-(9±39)-amide did not affect insulin release at 10 mmol/l glucose (data not shown). To verify that des-His
]-glucagonamide acts on human islets as a glucagon-receptor antagonist, we studied its effect on glucagon potentiation of 10 mmol/l glucose-induced release. Although glucagon potentiation of 10 mmol/l glucose-induced release was clearly present (p < 0.05), it was completely absent in the presence of des-His
]-glucagon-amide. Together, these data suggest that signalling of the human islet glucagon receptor not only mediates the potentiating effect of exogenously added glucagon but also, by the presence of endogenous glucagon, allows a permissive effect on insulin release from isolated islets.
mRNA analysis
Because of the restricted amount of cells available, we screened RNA from human islet cells for expression of GLP-1R, GIP-R and glucagon-receptor gene by semi-quantitative RT-PCR, using primer sets corresponding to the published sequences of the human receptors [25±27]. All four human islet cell preparations tested consistently expressed GLP-R, GIP-R and glucagon receptor as evidenced by the PCR fragments of the expected length (Fig. 2) and nucleotide sequence (data not shown). The 689 bp cDNA fragment corresponding to codons 199±429 of the human glucagon-receptor gene [27] was also amplified from human liver but not from lung, adipose tissue or adrenal gland. The amplified fragment which was identical to codons 203±431 of the GLP-1R cDNA [25] , was present not only in islets but also weakly visible in cDNA amplified from adrenal cortex. Finally, a cDNA fragment corresponding codons 195±384 of the GIP-R [26] was amplified from all human islet samples tested. More than one abundant PCR product for the GIP-R was present in one out of the four human islet cell preparations tested (HP102 in Fig. 2 ) but the sequence of the additional fragments is not known. In adrenal cortex as well as in liver very weak signals for amplicon(s) were present, but in adipose tissue the abundance of the amplified fragment was much stronger.
Sequence analysis of the adipocyte GIP-R fragment showed a variant in which a 61-bp segment corresponding to exon 8 of the gene was spliced out, encoding a truncated protein with a stop codon within a region corresponding to the fourth transmembrane helix (Fig. 3) . Unexpectedly, the shorter cDNA fragment from adipocytes had an abnormal (sligthly slower) electrophoretic mobility than the full length transcript.
Although each of the four human islet cell preparations tested clearly expressed glucagon receptor, GLP-1 and GIP receptors, one point of concern using the RT-PCR approach was that the positive signals might originate from transcripts expressed in non-endocrine cells present in these preparations, notably duct cells which cannot be fully separated from the endocrine cells with the current methods [17] . We therefore compared glucagon-receptor, GLP-1R and GIP-R mRNA abundance in human islet cells with purified duct cells [29] or total pancreas by northern blotting, a less sensitive technique than RT-PCR. Furthermore, with the same methods we assessed secretin-receptor gene expression as this receptor is known to be present on duct cells [31] . Human islet RNA strongly hybridised with the glucagon-receptor, GLP-1R and GIP-R cDNA probes but RNA extracted from duct cells was negative (Fig. 4) . Conversely, northern blots using the secretin cDNA probe were strongly positive for duct-cell RNA (Fig. 4 B) .
Discussion
Three decades ago, Cerasi and Luft applied the Sutherland model for cAMP-dependent signal transduction in mammalian cells [32] to the process of glucose regulation of the pancreatic beta cell and proposed that one pathophysiological mechanism of diabetes proceeds by loss of glucose-induced insulin release secondary to impaired signalling in beta cells [18] . Although it is now clear that direct glucose signalling is primarily metabolic [19, 20, 33±35] , i. e. not mediated by G protein-coupled membrane receptors, the idea that normal glucose responsiveness of islet beta cells depends on sufficient intracellular production of cAMP is still a focus of interest. The concept has been supported by various in vitro models of isolated rodent beta-cell preparations [36±38]. First, rat islets isolated from the dorsal, glucagon-rich, pancreas had a better insulin response to glucose than islets taken from the ventral lobe [36] , suggesting that paracrine glucagon up-regulated glucose responsiveness of beta cells. Second, flow-sorted and purified rat beta cells which are separated from their neighbouring glucagon-producing alpha cells [37] , have a poor secretory response to glucose [1] , despite their normal rates of glucose metabolism [33, 39] and glucose-induced insulin biosynthesis [40] . This selective secretory ªdeficiencyº was corrected by adding glucagonin nanomolar concentrations to the cells [1] which increased intracellular cAMP concentrations to the values observed in isolated islets [2] . We therefore proposed that the exquisite glucose responsiveness of intact islets is not only dependent on the process of glucose recognition but also on the presence of a certain threshold of intra-islet glucagon concentration which results in activation of glucagon receptors on beta cells [1±3] . Third, electrophysiological studies [38] have broadened this concept to other peptides of the secretin-glucagon family which can increase cAMP production in beta cells: addition of GLP-1 together with high glucose was necessary for full glucose-induced electrical activity in at least a subset of beta cells which were not glucose competent when glucose alone was used as a stimulus.
Analogous to what we have previously reported for the rat [1±4] we now find expression and functional activity of receptors recognising both glucagon and the incretin hormones GLP-1 and GIP in human islets. Furthermore, we observe that by pharmacological inhibition of glucagon-receptor activity using the potent glucagon-receptor antagonist des-His
]- Fig. 3 A, B. Comparison of GIP-R transcripts in pancreatic islets and adipose tissue. Alignment of GIP-R nucleotide sequence (A) and predicted amino-acid sequence (B) corresponding to the amplified and sequenced fragments (see glucagon-amide [28] can suppress to a major extent the glucose-responsiveness in these the cells. No such effect was seen with exendin-(9±39)-amide, a potent antagonist of the GLP-1-R [30] which was recently shown to block the incretin effect of GLP-1 in human subjects in vivo [24] . It has been debated, however, whether glucagon secreted from islet alpha cells has direct access to the receptive pole of beta cells [41, 42] . Morphometric data from rat pancreas indicate that arterioles perfusing medium size and large islets branch into capillaries within the betacell core before irrigating insulin-rich blood to the non-beta-cell mantle of the islet and emptying into extra-islet venules [41] . In other words, directionality of blood flow in this species does not favour the idea that glucagon released from alpha cells is preferentially interacting with islet beta cells, although neighbouring beta cells and interactions between alpha and beta cells in very small islets could be a special case. Furthermore, whereas regulation of rodent islet blood flow is relatively well understood [42] little is known about the microcirculation in human islets. Still to be investigated therefore is whether the existence of an important paracrine effect of glucagon, as detected in the present in vitro study, is relevant for the in vivo situation. It is well known from clinical practice that glucagon injection rapidly stimulates insulin secretion, but this is considered a pharmacological effect [13±15] . The possibility that a minimal threshold of paracrine glucagon is required to keep beta cells in a glucose competent state is much more difficult to test in vivo. Studies with glucagon receptor antagonists and mouse models with conditional knockout of the glucagon-receptor gene might be required for further analysis of this problem. Within this context it seems that some patients with Type II (non-insulin-dependent) diabetes mellitus have specific mutations in the glucagon-receptor gene [43] and that the Gly40Ser mutation results in an encoded G-protein coupled receptor which is more resistant to glucagon-induced cAMP formation [44] , indirectly suggesting that the hypothesis formulated by Cerasi and Luft [18] could have a clinical correlate for the same receptor as was studied by Sutherland [32] . The present data could also be relevant for drug development in Type II diabetes based on glucagon-receptor antagonism at the level of liver glucagon action.
When screening a number of control tissues for the expression of receptors of the secretin-glucagon family, we observed that human adipose tissue expressed a splice variant of the full-length GIP-R mRNA in which the 61-bp segment corresponding to exon 8 of the gene has been deleted. Of note, this variant seems to be the predominant GIP-R transcript in adipocytes [45] , whereas in human insulinoma it was reported to be a minor variant [45] . Rat adipocytes are known to express GIP-R [46] . Structure analysis indicates that a GIP-R-like protein truncated at the level of the predicted fourth transmembrane helix could be sufficient for GIP binding and (at least part of) receptor activity [47] but molecular mechanisms involved in receptor internalisation will probably be disturbed by this truncation [48] . It is not clear, however, to which extent GIP activation of lipolysis in human adipocytes contributes to the metabolic effects of this peptide in humans.
In conclusion, this study showing mRNA expression of glucagon receptors, GIP-Rs and GLP-1Rs in human islet cells correlates well with the measured in vitro effects of glucagon, GIP and GLP-1 on insulin release and the previously described in vivo effects of these peptides in human non-diabetic subjects. The potent effect of the glucagon-receptor antagonist desHis ]-glucagon-amide on glucose competence of insulin release from human beta cells suggests that this receptor could play a part in the control of insulin secretion in humans. Our data further support the idea that cAMP regulates glucose-induced insulin secretion at two levels: (i) ensuring a permissive effect, requiring minimal cyclic nucleotide concentrations, perhaps by local effects on islet glucagon and (ii) potentiating the effects of nutrients such as is observed for the gluco-incretin hormones GLP-1 and GIP.
